Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
options
options strategies
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Legend Biotech Corp ADR (LEGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

Legend Biotech CEO to Present Company Updates at 43rd Annual J.P. Morgan Healthcare Conference Quiver Quantitative, Inc. - Thu Dec 19, 5:24PM CST

Legend Biotech's CEO will present company updates at the J.P. Morgan Healthcare Conference on January 14, 2025.Quiver AI SummaryLegend Biotech Corporation announced that CEO Ying Huang, Ph.D., will present...

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference GlobeNewswire - Thu Dec 19, 7:01AM CST

Legend Biotech Reports 89% MRD Negativity in CARTITUDE-4 Study for CARVYKTI® in Multiple Myeloma After Three-Year Follow-Up Quiver Quantitative, Inc. - Tue Dec 10, 4:50AM CST

New data shows CARVYKTI® achieves 89% MRD negativity in multiple myeloma patients, significantly surpassing standard therapies.Quiver AI SummaryLegend Biotech has announced promising results from its...

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma GlobeNewswire - Mon Dec 9, 6:35PM CST

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights GlobeNewswire - Tue Nov 12, 6:00AM CST

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition GlobeNewswire - Thu Nov 7, 6:30AM CST

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma GlobeNewswire - Tue Nov 5, 8:10AM CST

Legend Biotech Appoints Alan Bash as President of CARVYKTI® GlobeNewswire - Mon Nov 4, 6:30AM CST

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results GlobeNewswire - Thu Oct 24, 7:00AM CDT

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia GlobeNewswire - Thu Oct 3, 6:30AM CDT